Adhera Therapeutics (Adhera Therapeutics) GF Value : $0.00 (As of May. 14, 2024)

View and export this data going back to 1993. Start your Free Trial

What is Adhera Therapeutics GF Value?

The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:

Historical multiples (PE Ratio, PS Ratio, PB Ratio and Price-to-Free-Cash-Flow) that the stock has traded at.
GuruFocus adjustment factor based on the company’s past returns and growth.
Future estimates of the business performance.

We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.

Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

As of today (2024-05-14), Adhera Therapeutics's share price is $0.0081. Adhera Therapeutics's GF Value is $0.00. Therefore, Adhera Therapeutics's Price-to-GF-Value for today is .

Based on the relationship between the current stock price and the GF Value, GuruFocus believes Adhera Therapeutics is Not Valued.

Adhera Therapeutics (OTCPK:ATRX) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

Posssible Evaluations	All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)	Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) There is only a sufficient margin of safety when the stock is undervalued.

Adhera Therapeutics's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	0.0081	/	0.00
	=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adhera Therapeutics GF Value Related Terms

Thank you for viewing the detailed overview of Adhera Therapeutics's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Adhera Therapeutics (Adhera Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adhera Therapeutics Inc (OTCPK:ATRX) » Definitions » GF Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

8000 Innovation Parkway, Baton Rouge, LA, USA, 70820

Website

https://www.adherathera.com

Adhera Therapeutics Inc is an emerging specialty biotech company that is strategically evaluating its focus including a return to a drug discovery and development company.

Executives

Zahed Subhan	director	8000 INNOVATION PARKWAY, BATON ROUGE LA 70820
Trond Kydd Waerness	director	8000 INNOVATION PARKWAY, BAON ROUGE LA 70820
Rice Charles L Jr	director	C/O ENTERGY CORPORATION LEGAL DEPT., 639 LOYOLA AVE., 26TH FLOOR, NEW ORLEANS LA 70113
Andrew Albert Kucharchuk	director, officer: Chief Executive Officer	549 MILGATE PLACE, BATON ROUGE LA 70810
Rhonda L. Stanley	officer: SVP Finance & Accounting	5001 SOUTH MIAMA BOULEVARD, SUITE 300, DURHAM NC 27703
Nancy R. Phelan	director	812 MAPLEWOOD ROAD, WAYNE PA 19087
Robert Eric Teague	officer: Chief Financial Officer	C/O MARINA BIOTECH, INC., 4721 EMPEROR BOULEVARD, SUITE 350, DURHAM NC 27703
Uli Hacksell	director	3911 SORRENTO VALLEY BOULEVARD, SAN DIEGO CA 92121
Robert Jr. Moscato	officer: CEO	400 PRATT STREET, SUITE 606, BALTIMORE MD 21202
Timothy Boris	director	805 AEROVISTA PLACE, SUITE 205, SAN LUIS OBISPO CA 93401
Isaac Blech	director	C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116
Peter D. Weinstein	officer: Chief Legal Officer	C.O MARINA BIOTECH, INC., 17870 CASTLETON STREET, SUITE 250, CITY OF INDUSTRY CA 91748
Amit B. Shah	officer: Chief Financial Officer	10 AGUILA, ALISO VIEJO CA 92656
Erik C. Emerson	officer: Chief Commercial Officer	2300 WEST SAHARA AVENUE, SUITE 800 - #4012, LAS VEGAS NV 89102
Mihir Munsif	officer: Chief Operating Officer	21102 BRIARWOOD LANE, TRABUCO CANYON CA 92679